Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 262735
  • calendar_today Published On: Jan, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Duchenne Muscular Dystrophy (DMD) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size is estimated to be worth US$ 1367.7 million in 2021 and is forecast to a readjusted size of USD 14630 million by 2028 with a CAGR of 40.3% during review period. Hospitals accounting for % of the Duchenne Muscular Dystrophy (DMD) Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Exondys segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Duchenne Muscular Dystrophy (DMD) Therapeutics include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, and Italfarmaco, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Duchenne Muscular Dystrophy (DMD) Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Exondys

Emflaza

Translarna

Market segment by Application, can be divided into

Hospitals

Clinics

Home Care

Market segment by players, this report covers

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Duchenne Muscular Dystrophy (DMD) Therapeutics, with revenue, gross margin and global market share of Duchenne Muscular Dystrophy (DMD) Therapeutics from 2019 to 2022.

Chapter 3, the Duchenne Muscular Dystrophy (DMD) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Duchenne Muscular Dystrophy (DMD) Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Duchenne Muscular Dystrophy (DMD) Therapeutics

1.2 Classification of Duchenne Muscular Dystrophy (DMD) Therapeutics by Type

1.2.1 Overview: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type in 2021

1.2.3 Exondys

1.2.4 Emflaza

1.2.5 Translarna

1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application

1.3.1 Overview: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Home Care

1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size & Forecast

1.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast by Region

1.5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region, (2017-2022)

1.5.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2017-2028)

1.5.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2017-2028)

1.5.6 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers

1.6.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints

1.6.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Trends Analysis

2 Company Profiles

2.1 Sarepta Therapeutics

2.1.1 Sarepta Therapeutics Details

2.1.2 Sarepta Therapeutics Major Business

2.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Sarepta Therapeutics Recent Developments and Future Plans

2.2 PTC Therapeutics

2.2.1 PTC Therapeutics Details

2.2.2 PTC Therapeutics Major Business

2.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 PTC Therapeutics Recent Developments and Future Plans

2.3 Pfizer

2.3.1 Pfizer Details

2.3.2 Pfizer Major Business

2.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Pfizer Recent Developments and Future Plans

2.4 Bristol-Myers Squibb

2.4.1 Bristol-Myers Squibb Details

2.4.2 Bristol-Myers Squibb Major Business

2.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans

2.5 Italfarmaco

2.5.1 Italfarmaco Details

2.5.2 Italfarmaco Major Business

2.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Italfarmaco Recent Developments and Future Plans

2.6 Santhera Pharmaceuticals

2.6.1 Santhera Pharmaceuticals Details

2.6.2 Santhera Pharmaceuticals Major Business

2.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

2.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Santhera Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2021

3.2.2 Top 10 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Head Office, Products and Services Provided

3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Mergers & Acquisitions

3.5 Duchenne Muscular Dystrophy (DMD) Therapeutics New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Type (2017-2022)

4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2017-2022)

5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2028)

6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2028)

6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

6.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2017-2028)

6.3.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

6.3.3 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

6.3.4 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2028)

7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2028)

7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

7.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2017-2028)

7.3.2 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

7.3.3 France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

7.3.5 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

7.3.6 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2028)

8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2028)

8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region

8.3.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region (2017-2028)

8.3.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

8.3.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

8.3.4 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

8.3.5 India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

8.3.7 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2028)

9.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2028)

9.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

9.3.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2017-2028)

9.3.2 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

9.3.3 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2028)

10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2028)

10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

10.3.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2017-2028)

10.3.2 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

10.3.4 UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) by Region (2017-2022)

Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Region (2023-2028)

Table 6. Sarepta Therapeutics Corporate Information, Head Office, and Major Competitors

Table 7. Sarepta Therapeutics Major Business

Table 8. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 9. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. PTC Therapeutics Corporate Information, Head Office, and Major Competitors

Table 11. PTC Therapeutics Major Business

Table 12. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 13. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Pfizer Corporate Information, Head Office, and Major Competitors

Table 15. Pfizer Major Business

Table 16. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 17. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors

Table 19. Bristol-Myers Squibb Major Business

Table 20. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 21. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Italfarmaco Corporate Information, Head Office, and Major Competitors

Table 23. Italfarmaco Major Business

Table 24. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 25. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Santhera Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 27. Santhera Pharmaceuticals Major Business

Table 28. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions

Table 29. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 32. Breakdown of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)

Table 33. Duchenne Muscular Dystrophy (DMD) Therapeutics Players Head Office, Products and Services Provided

Table 34. Duchenne Muscular Dystrophy (DMD) Therapeutics Mergers & Acquisitions in the Past Five Years

Table 35. Duchenne Muscular Dystrophy (DMD) Therapeutics New Entrants and Expansion Plans

Table 36. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) by Type (2017-2022)

Table 37. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2017-2022)

Table 38. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Type (2023-2028)

Table 39. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2022)

Table 40. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Application (2023-2028)

Table 41. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 42. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 43. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 44. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 45. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 46. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2023-2028) & (USD Million)

Table 47. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 48. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 49. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 50. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 51. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 52. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2023-2028) & (USD Million)

Table 53. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 54. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 55. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 56. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 57. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region (2017-2022) & (USD Million)

Table 58. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region (2023-2028) & (USD Million)

Table 59. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 60. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 61. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 62. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 63. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 64. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2023-2028) & (USD Million)

Table 65. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 66. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 67. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 68. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 69. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 70. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Picture

Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type in 2021

Figure 3. Exondys

Figure 4. Emflaza

Figure 5. Translarna

Figure 6. Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application in 2021

Figure 7. Hospitals Picture

Figure 8. Clinics Picture

Figure 9. Home Care Picture

Figure 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Forecast (2017-2028) & (USD Million)

Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Region (2017-2028)

Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Region in 2021

Figure 14. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers

Figure 20. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints

Figure 21. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends

Figure 22. Sarepta Therapeutics Recent Developments and Future Plans

Figure 23. PTC Therapeutics Recent Developments and Future Plans

Figure 24. Pfizer Recent Developments and Future Plans

Figure 25. Bristol-Myers Squibb Recent Developments and Future Plans

Figure 26. Italfarmaco Recent Developments and Future Plans

Figure 27. Santhera Pharmaceuticals Recent Developments and Future Plans

Figure 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players in 2021

Figure 29. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 30. Global Top 3 Players Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share in 2021

Figure 31. Global Top 10 Players Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share in 2021

Figure 32. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 33. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type in 2021

Figure 34. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Type (2023-2028)

Figure 35. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application in 2021

Figure 36. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Application (2023-2028)

Figure 37. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 38. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 39. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Country (2017-2028)

Figure 40. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 41. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 42. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 43. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 44. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 45. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Country (2017-2028)

Figure 46. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. France Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. United Kingdom Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 52. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 53. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Region (2017-2028)

Figure 54. China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. India Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 61. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 62. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Country (2017-2028)

Figure 63. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Type (2017-2028)

Figure 66. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share by Application (2017-2028)

Figure 67. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Country (2017-2028)

Figure 68. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Methodology

Figure 72. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz